The publisher explores Lundbeck’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (4 November 2020)
Model updates (13 August 2020)
Model updates (12 May 2020)
Model updates (6 February 2020)
Snapshot
- Overview - Lundbeck’s prescription pharmaceutical sales are set to grow over the forecast period.
- Key themes - [1] Key CNS products are expected to drive continued growth [2] Generic market entries will erode sales of five drugs [3] Acquisition of Alder BioPharmaceuticals adds Vyepti to Lundbeck’s product portfolio.
Model updates (4 November 2020)
- Cipralex forecast adjusted higher in Rest of World
- Onfi forecast adjusted higher due to better-than-expected performance given generic competition
- Trintellix forecast adjusted lower in Europe.
Model updates (13 August 2020)
- Rexulti forecast adjusted higher due to continued strong uptake in the US across schizophrenia and major depressive disorder.
- Rexulti forecast adjusted lower in 5EU and Rest of World due to current trends as well as the discontinuation for bipolar disorder.
Model updates (12 May 2020)
- Eptinezumab name changed to Vyepti.
Model updates (6 February 2020)
- Eptinezumab added to forecast after acquisition of Alder BioPharmaceuticals for $1.95bn.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
